Ridaifen A is a tamoxifen derivative. Like other ridaifens, ridaifen A may exhibit anticancer activity. Related compound ridaifen B increases ROS levels and mitochondria-mediated apoptosis in breast cancer cells. Related compound ridaifen F inhibits the proteasome.
| Purity | ≥98% |
|---|---|
| Formula | C30H38N2O2 • 2HCl |
| Formula Wt. | 531.56 |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | R3312 Info Sheet PDF |
|---|
Hasegawa M, Yasuda Y, Tanaka M, et al. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. Eur J Med Chem. 2013 Nov 16;71C:290-305. PMID: 24321833.
Guo WZ, Shiina I, Wang Y, et al. Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway. Biochem Pharmacol. 2013 Nov 1;86(9):1272-84. PMID: 23973528.
Nagahara Y, Shiina I, Nakata K, et al. Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B. Cancer Sci. 2008 Mar;99(3):608-14. PMID: 18167132.
